PDF(Pubmed)
Abstract：
UNASSIGNED: The mortality rate of ovarian cancer (OC) ranks first among female genital tract malignant tumors, which seriously threatens women\'s life and health. Because of its insidious onset and poor prognosis, it has become a thorny problem in the clinic, especially for patients with platinum-resistant recurrent ovarian cancer (PROC). In recent years, the medical treatment of OC has made gratifying results, bringing hope to the patients.
UNASSIGNED: A 54-year-old OC patient who has failed previous neoadjuvant chemotherapy, cytoreductive surgery, and postoperative chemotherapy was diagnosed with PROC. Then she received combination treatment of fuzuloparib (100mg PO BID), apatinib (250mg PO QD), and camrelizumab (200mg IV Q3W) for every 3-week cycle in a Phase II study for PROC patients. In the phase II study, her condition stabilized, responded well to treatment with a sharp decrease by 91.14% of target lesions and disappearances of non-target lesions, and continued to receive regular treatment with progression-free survival exceeding 15 months and no serious adverse events.
UNASSIGNED: The present case proves PROC patients might have a sustained response to triplet combination with camrelizumab, combined with fuzuloparib and apatinib.
UNASSIGNED: A 54-year-old OC patient who has failed previous neoadjuvant chemotherapy, cytoreductive surgery, and postoperative chemotherapy was diagnosed with PROC. Then she received combination treatment of fuzuloparib (100mg PO BID), apatinib (250mg PO QD), and camrelizumab (200mg IV Q3W) for every 3-week cycle in a Phase II study for PROC patients. In the phase II study, her condition stabilized, responded well to treatment with a sharp decrease by 91.14% of target lesions and disappearances of non-target lesions, and continued to receive regular treatment with progression-free survival exceeding 15 months and no serious adverse events.
UNASSIGNED: The present case proves PROC patients might have a sustained response to triplet combination with camrelizumab, combined with fuzuloparib and apatinib.
摘要：
未经证实：卵巢癌（OC）的死亡率在女性生殖道恶性肿瘤中排名第一，严重威胁女性的生命和健康。由于其发病隐匿，预后差，这已经成为诊所的一个棘手问题，尤其是铂耐药复发性卵巢癌（PROC）患者。近年来,OC的医疗取得了可喜的成果，给患者带来希望。
未经批准：一名54岁的OC患者，先前新辅助化疗失败，细胞减灭术,术后化疗诊断为PROC。然后她接受了fuzuloparib（100mgPOBID）的联合治疗，阿帕替尼（250mgPOQD），在一项针对PROC患者的II期研究中，每3周周期使用卡姆雷珠单抗（200mgIVQ3W）。在第二阶段研究中，她的病情稳定了,对治疗反应良好，靶病变和非靶病变消失率急剧下降91.14%，继续接受常规治疗,无进展生存期超过15个月,无严重不良事件.
UNASSIGNED：目前的病例证明，PROC患者可能对卡姆瑞珠单抗三联疗法有持续的反应，联合福祖洛帕尼和阿帕替尼。
未经批准：一名54岁的OC患者，先前新辅助化疗失败，细胞减灭术,术后化疗诊断为PROC。然后她接受了fuzuloparib（100mgPOBID）的联合治疗，阿帕替尼（250mgPOQD），在一项针对PROC患者的II期研究中，每3周周期使用卡姆雷珠单抗（200mgIVQ3W）。在第二阶段研究中，她的病情稳定了,对治疗反应良好，靶病变和非靶病变消失率急剧下降91.14%，继续接受常规治疗,无进展生存期超过15个月,无严重不良事件.
UNASSIGNED：目前的病例证明，PROC患者可能对卡姆瑞珠单抗三联疗法有持续的反应，联合福祖洛帕尼和阿帕替尼。
